Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$57.4MCash on Hand
16.6mo Cash Runway
Follow GYRE by emailGet an email when GYRE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GYRE, unsubscribe in one click. Privacy
📣 What GYRE Says Is Next
mid-2027 · “Dual-degrader programs (next-generation targeted protein degraders) Gyre expects to submit Investigational New Drug (IND) applications and initiate Phase 1 clinical trials, upon regulatory approval of IND applications, in the United States and/or China around mid-2027 for CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases.”
Company press release, Nov 5, 2026 · SEC filing
second half of 2027 · “We anticipate Phase 1 dose-escalation data to be available in the second half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
first quarter of 2027 · “Dual-degrader programs, next-generation TPDs: Gyre expects to submit Investigational New Drug (IND) applications in the United States and/or China in the first quarter of 2027 for two additional Cullgen degrader assets: CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases.”
Company press release, Aug 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Earnings Q3 2026 revenue was $32.9 million, flat versus $32.7 million a year earlier, with GAAP basic EPS of $(0.04). Full-year 2026 revenue guidance of $100.5 to $111.0 million was affirmed, and cash totaled $98.8 million at September 30, 2026. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Leadership Gyre entered employment agreements on October 16, 2026, with CEO Ying Luo, Ph.D. ($500,000 base salary, $150,000 target 2026 bonus) and CFO Thomas Eastling ($339,066 base salary, $70,000 target 2026 bonus), including severance and change-of-control terms. Form 8-K · SEC filing
Sep 1, 2026 ·
Gyre Therapeutics made available an updated corporate presentation on its website, furnished as Exhibit 99.1. The presentation covers its degrader pipeline, China operations and FY26 ETUARY revenue guidance of $100.5M-$111M. Form 8-K · SEC filing · Press release
Aug 26, 2026 ·
Gyre Therapeutics made available an updated corporate presentation on its website, furnished as Exhibit 99.1. The presentation covers its degrader platform, China commercial operations, and pipeline catalysts, including a Q1'27 regulatory milestone for CG923308. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
GYRE holds $57.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.4M/quarter from operations,
an estimated runway of 16.6 months at that rate (BioRadar estimate, not company guidance).
Share count 115,321,017 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GYRE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GYRE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.